OverviewSuggest Edit

Vitality Biopharma focuses on the development of cannabinoids for the treatment of neurological and inflammatory disorders, such as inflammatory bowel disease and multiple sclerosis. Its products in pipeline include Cannabosides - VITA-100 for gastrointestinal disorders, including inflammatory bowel disease and irritable bowel syndrome; Cannabosides - VITA-210 for muscle spasticity in multiple sclerosis and rare white matter disorders; and Cannabosides for epilepsy, schizophrenia, substance abuse and Huntington's disease.

TypePublic
Founded2012
HQLos Angeles, US
Websitevitality.bio

Latest Updates

Employees (est.) (Jul 2019)8(+15%)
Revenue (FY, 2019)$258.3 K(+153%)
Share Price (Oct 2017)$2 (+3%)

Key People/Management at Vitality Biopharma

Robert Brooke

Robert Brooke

CEO, Co-Founder
Avtar Dhillon

Avtar Dhillon

Chairman & Co-Founder
Richard McKilligan

Richard McKilligan

Controller
Anthony Maida

Anthony Maida

Director, Chair of Audit Committee
Brandon Zipp

Brandon Zipp

Director of R&D, Scientific Co-Founder
Tracy Rockney

Tracy Rockney

Senior Regulatory Advisor
Show more

Vitality Biopharma Office Locations

Vitality Biopharma has an office in Los Angeles
Los Angeles, US (HQ)
1901 Avenue of the Stars 2nd Floor
Show all (1)

Vitality Biopharma Financials and Metrics

Vitality Biopharma Revenue

Vitality Biopharma's revenue was reported to be $258.29 k in FY, 2019
USD

Revenue (FY, 2019)

258.3k

Net income (FY, 2019)

(13.1m)

EBIT (FY, 2019)

(13.2m)

Market capitalization (8-Oct-2018)

38.8m

Cash (31-Mar-2019)

6.0m
Vitality Biopharma's current market capitalization is $38.8 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

248.3k163.4k102.4k258.3k

Revenue growth, %

(34%)(37%)

Cost of goods sold

149.5k108.3k77.9k

Gross profit

98.9k55.1k24.5k
Quarterly
USDQ2, 2017Q3, 2017Q2, 2018

Revenue

45.9k39.7k31.0k

Cost of goods sold

20.9k19.9k17.5k

Gross profit

25.0k19.8k13.5k

Gross profit Margin, %

54%50%44%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

1.4m389.7k95.4k1.2m656.3k6.0m

Accounts Receivable

61.6k30.4k19.2k13.8k19.4k

Inventories

8.5k6.5k

Current Assets

1.4m6.1m
Quarterly
USDQ2, 2014Q1, 2015Q1, 2016Q2, 2016Q3, 2016Q2, 2017Q3, 2017Q2, 2018

Cash

551.3k830.1k1.2m692.7k208.1k33.7k153.8k815.5k

Accounts Receivable

27.9k43.3k42.9k76.8k27.9k32.2k20.2k

Inventories

15.9k8.5k9.4k7.9k6.5k6.5k

Current Assets

637.2k
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(4.2m)(4.0m)(141.3k)(5.2m)(4.3m)(13.1m)

Depreciation and Amortization

12.3k

Inventories

(8.5k)2.0k6.5k

Accounts Payable

107.7k4.1k110.9k158.1k(173.2k)285.9k
Quarterly
USDQ1, 2016

Net Income

215.6k

Accounts Payable

25.8k

Cash From Operating Activities

(486.4k)

Cash From Financing Activities

1.3m
USDY, 2019

Revenue/Employee

36.9k

Financial Leverage

1.2 x
Show all financial metrics

Vitality Biopharma Online and Social Media Presence

Embed Graph

Vitality Biopharma News and Updates

Vitality Biopharma Co-Founder Dr. Avtar Dhillon Resigns from Board of Directors

LOS ANGELES, April 25, 2019 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious n…

Vitality Biopharma Appoints Former Ohio Governor Richard F. Celeste to Board

LOS ANGELES, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious ne…

Vitality Biopharma Announces Corporate Updates and Completion of an SEC Examination

LOS ANGELES, Nov. 21, 2018 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma”, “Vitality”, or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neu…

Vitality Biopharma Scientific Co-Founder to Present Recent Data at CannMed Medical Conference in Los Angeles

Dr. Brandon Zipp to discuss outlook for Vitality’s VBX-100 THC prodrug in scientific presentation held at UCLA Dr. Brandon Zipp to discuss outlook for Vitality’s VBX-100 THC prodrug in scientific presentation held at UCLA

Vitality Biopharma THC Prodrug VBX-100 Demonstrates Positive Safety Results

-  During safety pharmacology screening Vitality’s THC prodrug demonstrates no signs of adverse or off-target effects -  During safety pharmacology screening Vitality’s THC prodrug demonstrates no signs of adverse or off-target effects 

Vitality Biopharma Blogs

Vitality Biopharma Welcomes New Executive Management Team

– Appointment of Current Director Michael Cavanaugh as Interim Chief Executive Officer – – Promotion of Current Controller and Counsel Richard McKilligan to Chief Financial Officer – LOS ANGELES, CA (MARKETWIRED – May 14, 2019) – Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality” or the “Company”),…

Vitality Biopharma to Present at the 11th Annual LD Micro Main Event

LOS ANGELES, CA – (GLOBE NEWSWIRE – December 3, 2018) — Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and in…

Vitality Biopharma Receives $8.5 Million Common Stock Financing

Financing to support company at least into 2020 and for the initiation of multiple Phase 2 clinical trials LOS ANGELES, CA – (October 23, 2018) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma”, “Vitality”, or the “Company”) a corporation dedicated to the development of cannabinoid prod…

Vitality Biopharma Announces Neural Repair Treatment Patent Filings

Focused on remyelination, a form of neural repair that may benefit multiple sclerosis as well as addiction, stroke, and schizophrenia LOS ANGELES, CA – (October 3, 2018) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid p…

Vitality Biopharma Frequently Asked Questions

  • When was Vitality Biopharma founded?

    Vitality Biopharma was founded in 2012.

  • Who are Vitality Biopharma key executives?

    Vitality Biopharma's key executives are Robert Brooke, Avtar Dhillon and Richard McKilligan.

  • How many employees does Vitality Biopharma have?

    Vitality Biopharma has 8 employees.

  • What is Vitality Biopharma revenue?

    Latest Vitality Biopharma annual revenue is $258.3 k.

  • What is Vitality Biopharma revenue per employee?

    Latest Vitality Biopharma revenue per employee is $32.3 k.

  • Who are Vitality Biopharma competitors?

    Competitors of Vitality Biopharma include Opiant Pharmaceuticals, IntelGenx and Mylan.

  • Where is Vitality Biopharma headquarters?

    Vitality Biopharma headquarters is located at 1901 Avenue of the Stars 2nd Floor, Los Angeles.

  • Where are Vitality Biopharma offices?

    Vitality Biopharma has an office in Los Angeles.

  • How many offices does Vitality Biopharma have?

    Vitality Biopharma has 1 office.